Qiagen

Decent end to 2024

06/02/25 -"Qiagen’s Q4 24 results aligned with market expectations and slightly exceeded management’s guidance. Most segments demonstrated healthy sales growth. While mid-single-digit growth is ..."

PDF page sample
Pages
66
Language
English
Published on
06/02/25
Download
You may also be interested by these reports :
29/07/26
bioMerieux’s H1 profitability largely met expectations. Q2 sales growth was driven by increases across both segments, supported by its GO28 growth ...
28/07/26
Philips’ Q2 sales surpassed expectations, with profitability excluding one-offs meeting forecasts. The 2026 guidance was reaffirmed. However, ...
24/07/26
Sartorius reported mixed Q2 26 numbers, with revenue below consensus (-2.3%) but underlying EBITDA slightly ahead (+0.5%). Equipment inflected as ...
23/07/26
Sartorius Stedim Biotech reported mixed Q2 26 numbers, with revenue below consensus (-2.8%) but underlying EBITDA ahead (+1.1%). The miss is largely ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO